1883429-22-8

Basic information

• Product Name: BI-9564
• Synonyms: BI-9564
• CAS NO: 1883429-22-8
• Molecular Formula: C20H23N3O3
• Molecular Weight: 353.41492
• Mol File: 1883429-22-8.mol

Chemical Properties

• Appearance: /
• Solubility: ≥8.82 mg/mL in DMSO with ultrasonic,≥8.32 mg/mL in EtOH with ultrasonic,insoluble in H2O
• CAS DataBase Reference: BI-9564(CAS DataBase Reference)
• NIST Chemistry Reference: BI-9564(1883429-22-8)
• EPA Substance Registry System: BI-9564(1883429-22-8)

Safety Data

• Hazardous Substances Data: 1883429-22-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-[4-[(Dimethylamino)methyl]-2,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One is used as a pharmaceutical compound for its potential therapeutic applications. The compound's unique structure may allow it to interact with specific biological targets, making it a candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, 4-[4-[(Dimethylamino)methyl]-2,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One can be used as a starting material or a building block for the synthesis of more complex molecules with specific properties and functions.
Used in Drug Delivery Systems:
Similar to gallotannin, 4-[4-[(Dimethylamino)methyl]-2,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One may also be employed in the development of novel drug delivery systems. Its unique chemical properties could be utilized to improve the delivery, bioavailability, and therapeutic outcomes of various drugs.
Used in Epigenetic Research:
4-[4-[(Dimethylamino)methyl]-2,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One can be used as an epigenetic probe to study the role of specific protein-DNA interactions in gene regulation and other cellular processes. This could provide valuable insights into the development of new therapeutic strategies for various diseases.

in vitro

bi-9564 was identified as a brd9/7 specific inhibitor via fragment-based screening and structure-guided design. bi-9564 was found to be bind to brd9 with a higher affinity than to brd7, and was negative on bet family proteins. in addition, bi-9564 demonstrated in vitro off-target selectivity to cecr2, but not in cells [1].

in vivo

in animal study, bomtac:nmrifoxn1nu mice were given two oral doses daily and the concentration of bi-9564 in plasma was measured. dose-dependent aucs were obtained for bi-9564, achieving exposures that were higher compared to the ec50 level for eol-1 cells. moreover, when the oral treatment with bi-9564 at 180 mg/kg was initiated on day 5 and applied daily with an interruption at day 18 and 19, a significant reduction in tumour growth compared to controls was found on day 18 leading to a median tumour growth inhibition value of 52% [1].

IC 50

75 nm and 3.4 μm for brd9 and brd7 bromodomains, respectively

references

[1] martin lj et al. structure-based design of an in vivo active selective brd9 inhibitor. j med chem. 2016 may 26;59(10):4462-75.